äžçã®éèç §æè£ 眮åžå Ž èŠæš¡ããã³ã·ã§ã¢åæ - æé·ãã¬ã³ãããã³äºæž¬ (2025-2032)
äžçã®éèç §æè£ 眮åžå Žã¯ãæè¡å¥ïŒèµ€å€ç·ãéèŠãè¶ é³æ³¢ããã®ä»ïŒãçšéå¥ïŒéèã¢ã¯ã»ã¹ãæ¡è¡ãæè¡ããã®ä»ïŒããšã³ããŠãŒã¶ãŒå¥ïŒç é¢ãç®è¡ãã£ã³ããåŠè¡æ©é¢ããã®ä»ïŒãå°åå¥ïŒåç±³ããšãŒããããã¢ãžã¢...
äžçã®éèç §æè£ 眮åžå Ž ãµã€ãº - åæ
äžçã®éèç §æè£ 眮åžå ŽèŠæš¡ã¯è©äŸ¡ããããšæšå®ãããŸã US$ 747.4 Mn ã§ 2025 ãš US$ 1532.3 ã«å°éãããããžã§ã¯ã 2032幎ãŸã§ã®10.8%ã®ååç©ã®å¹Žéæé·ç(CAGR)ã2025幎ãã2032幎ãŸã§å±ç€ºã éèã®ã€ã«ãããŒã·ã§ã³è£ 眮ã¯ç®ã®è¡šé¢ã®äžã®éèãèŠèŠåããã®ã«äœ¿çšãããŠããŸãã è¡ã«ãã£ãŠåžåãããç®ã®è¡šé¢ã®ãããã³ã°ãšããŠéèã®ãã¿ãŒã³ã衚瀺ããããã«åæ ãããç®ã®è¿èµ€å€ç·ã©ã€ãããåããŸãã ãããã®è£ 眮ã¯éè(IV)ã®ã¢ã¯ã»ã¹ããã³è¡ã®åŒã®ããã·ãŒãžã£ã®ããã«äž»ã«äœ¿çšãããŸãã åžå Žæé·ãæšé²ããéèŠãªèŠå ã¯ãæ ¢æ§çŸæ£ã®èå»¶ãå¢å ãããèã®äººå£ãå¢å ãããéèç §ææ©åšã®é²æ©ãããŒãã«ã¯æèãé«ããŠããŸãã
äžçã®éèã®ç §æè£ 眮åžå Žã¯æè¡ãé©çšããšã³ã ãŠãŒã¶ãŒããã³å°åã«åããããŸãã ãã¯ãããžãŒã«ãã£ãŠãåžå Žãã¬ã€ã€ãŒã«ããèµ€å€ç·æŸå°è£ 眮ã®ç¶ç¶çãªæäŸã«ãã2025å¹Žã®æå€§ã®åžå Žã·ã§ã¢ã®ããã«èæ ®ãããèµ€å€ç·æŸå°ã®åºåã
äžççãªéèã®ç §æè£ 眮åžå Žã®é転è
- éèã®ãã¡ã€ã³ããŒã®æè¡éçº: éèç §æããã³ã€ã¡ãŒãžã³ã°æè¡ã®ç¶ç¶çãªé²æ©ã¯ãéèç §æè£ 眮ã®åžå Žã®æé·ãçæåããŠããŸãã äŒæ¥ã¯ãããåºãèŠéãããé«ãããŒã¿ããªãã£ãã¹ããŒããã©ã³ã®æ¥ç¶æ§ãããã³ãŠã§ã¢ã©ããªãã£ãåããéçºæ©åšã«çŠç¹ãåœãŠãŠããŸãã ããšãã°ãAccuVein Inc.ã¯å»çæ©åšã¡ãŒã«ãŒã®AV400ã¯ãæå€§10 mmã®æ·±ãã§éèãèŠèŠåããã®ã«åœ¹ç«ã¡ãŸãã åæ§ã«ãVeinViewerã¯æ°ããç¡ç·éèã®ãã¡ã€ã³ããŒãæéŠã§èº«ã«ã€ããããšãã§ããŸãã ãã®ãããªæè¡é©æ°ã¯ãåžå Žæé·ãæšé²ããŠããŸãã
- éèç §æè£ 眮ã«ã€ããŠã®æèãé«ãã: éèç §æè£ 眮ã®å©ç¹ã«ã€ããŠãå»çåŸäºè ãšæ£è ã®æèãé«ããããšã¯ãåžå Žæé·ãä¿é²ããŠããŸãã ãããã®ããã€ã¹ã¯ãè¡ç®¡ã¢ã¯ã»ã¹ãæ¹åããæé æéãæžããã ãã§ãªããçã¿ããã³ã¯ã®è©Šã¿ãæå°éã«æããããšã«ãã£ãŠæ£è ã®çµéšãé«ããã ãã§ãªããã å»çã®ç€ŸäŒã¯ãããå®å šãªèšåºå®è·µã®ããã®éèç §æè£ çœ®ãæšé²ããŠããŸãã äŒè°ããã£ã³ããŒã³ããã¬ãŒãã³ã°ããã°ã©ã ãéããæèãé«ããããšã§ããããªãçæåãé²ãã§ããŸãã
- æè¡ä»¶æ°ã®å¢å : : : ã°ããŒãã«ã§ã¯ãæ¯å¹Žãæè¡åæ°ãå¢å ããŠããŸãã ããå€ãã®äººã ã¯ããŸããŸãªå»åŠã®ç¶æ ãæ±ãããã«å€ç§åŠçœ®ãéžã¶ããšã§ãã å€ç§ç容ç©ã®ãã®äžæã¯å šäœçãªéèã®ç §æè£ 眮ã®åžå Žã®æé·ãé転ããéèŠãªèŠå ã®1ã€ã§ãã éèæ¢ç¥ãŸãã¯éèãã¥ãŒã¢ãšãåŒã°ããéèç §æè£ 眮ã¯ãIVæ¶²ã®æäžãè¡æ¶²ãµã³ãã«ã®æç»ãããŸããŸãªè¡ç®¡ã¢ã¯ã»ã¹æé ãå®è¡ãããªã©ãå€ãã®å€ç§çæé ã§äœ¿çšãããå¿ é å»çæ©åšã§ãã æè¡ã¯ä¿¡é Œã§ããéèã¢ã¯ã»ã¹ãå¿ èŠãšããããããããã®éèç §æè£ 眮ã«å¯ŸããèŠæ±ã¯ãæè¡å®€ãšå€å·ã»ã³ã¿ãŒããå¢å ããŠããŸãã äŸãã°ãäžçä¿å¥æ©é¢(WHO)ã®ããŒã¿ã«ãããšã230ãè¶ ãã Mn ã®äž»èŠãªå€ç§æè¡æé 㯠2018 幎ã«ã°ããŒãã«ã«è¡ããã2012 幎æ°ãšæ¯èŒããŠçŽ 20% å¢å ããŸããã 2025幎ãŸã§ã«15%以äžã®æé·ãäºå®ããŠããŸãã
äžçã®éèã®ç §æè£ 眮åžå Žæ©äŒ
- æ°èåœã¯éèŠãªæé·ã®éã衚ããŸã: ã¢ãžã¢ãã·ãã£ãã¯ãäžåç±³ãã¢ããªã«è«žåœã®åœã ãçºå±ãããå»çã€ã³ãã©ã®æŽåããã«ã¹ã±ã¢ã®æ®åãèªç¥åºŠåäžãªã©ããã€ã³ã€ã«ãããŒã·ã§ã³ããã€ã¹äŒæ¥ã«æå©ãªæé·æ©äŒãæäŸããŸãã ãããã®å°åã®å€§ããªä¿è·ãããæ£è ããŒã«ãäž»èŠãªããžãã¹ã®èŠéãã瀺ããŠããŸãã ããŒã«ã«è£œé ãšæµéã®ããŒãããŒã·ããã«ãããäŒæ¥ãæ°èåœã«ãããå°ççãããããªã³ããæ¡å€§ããããšãã§ããŸãã
- æå°éã®äŸµè¥²æè¡ã®å¥œã¿ãã·ãã: éå»10幎éãäžçåå°ã®äŒçµ±çãªãªãŒãã³æè¡ã«é¢ããæäœéã®äŸµè¥²çæè¡ã®æé ãçå®ã«å¢å ããŸããã ãã®ã·ããã¯ãããã«æé·ããããã«ãéèç §æããã€ã¹åžå Žã®ããã®å·šå€§ãªæ©äŒãæäŸããŠããŸãã æå°äŸµè¥²æè¡ã¯ãæ£è ãããè¿ éãªå埩æéãããå°ããåéãããã³å·ãžã®ããå°ãªãå€å·ãåŒãèµ·ãããŸãã varicoseéèã®åŠçœ®ãhaemorrhoidectomyããã³ç®¡ã®ã¢ã¯ã»ã¹ã®ãããªããã·ãŒãžã£ã¯å éšã¬ãŒã¶ãŒã®ablationãæŸå°åšæ³¢æ°ã®ablationãããã³åŸæ¥ã®é€å»ãçµçŽ®ã®å€ç§ãããããä»ã®ãããªæå°éã«äŸµè¥²çãªæè¡ã䜿çšããããšã«ãã£ãŠãŸããŸããŸããŸãè¡ããŸãã ããšãã°ãHHSãããªãã¯ã¢ã¯ã»ã¹ãå ¬è¡šããèšäºã«ãããšã2025幎1æ1æ¥ã2017幎ã9.8 Mnã€ã³ããã£ãšã³ãäž»èŠãªæè¡å®€æé ãåæããããã®11.1%ãMISãš2.5%ããããã£ãã¯ã¢ã·ã¹ãããã2018幎ã«9.6 Mnã€ã³ããã£ãšã³ãæè¡å®€æé (11.2% MISãš 2.9% ãããã£ãã¯ã¢ã·ã¹ã)ãšæ¯èŒããŠããŸããã
äžççãªéèã®ç §æè£ 眮åžå Žã®æå¶
- éèã®èŠèŠåè£ çœ®ã®é«ãã³ã¹ã: ç¹ã«éçºå°åã«ãããéèç §æåšãã€ã¡ãŒãžã£ãŒãããã³ä»å±åã®ãã³ããŒã®æ¡çšã®é«ã³ã¹ãã éèèŠèŠåè£ çœ®ã®ããã®äŸ¡æ Œã¯US $ 2500-3500ã®ç¯å²ã§ãã ã¡ã³ããã³ã¹ãšäº€æã®åçºã³ã¹ããçµè²»ã«å ç®ãããŸãã ããã¯ãäºç®ã®å¶çŽãæã€å°ããªã¯ãªããã¯ãç é¢ã®ããã«æ¡çšå°é£ã«ãªããŸãã
ã«ãŠã³ã¿ãŒãã©ã³ã¹: äž»èŠãªåžå Žãã¬ãŒã€ãŒã¯éçºå°åã«ãã£ãŠæé ãªäŸ¡æ Œã«ãªãè²»çšå¹æã倧ãã解決ãå°å ¥ããããšã«çŠç¹ãåãããªããã°ãªããŸããã
- å»çåŸäºè ã®ãã¬ãŒãã³ã°ã®æ¬ åŠ: éèèŠèŠåè£ çœ®ã®äœ¿çšã«é¢ããååãªèšç·Žãšæèã®æ¬ åŠã¯ããã«ã¹ã±ã¢èšå®ã®æ¡çšãå¶éããŸãã äžé©åãªè£ 眮ã®äœ¿çšã¯èŠèŠåã®è³ªãæãªãããšãã§ããŸãã å»åŠã®åŠæ ¡ã¯é »ç¹ã«ã«ãªãã¥ã©ã ã®éèã®ãã¡ã€ã³ããŒã®èšç·Žãå«ãã§ããŸããã
ã«ãŠã³ã¿ãŒãã©ã³ã¹: äŒæ¥ã¯ãèšåºå»ã®å®æçãªãã¬ãŒãã³ã°ã¯ãŒã¯ã·ã§ããããã¬ãŒãã³ã°ã宿œããããã€ã¹ã®å©çšãä¿é²ããªããã°ãªããŸããã
- è¥æºæ£è ã«ãããéèãã¡ã€ã³ããŒã®å¶é: æ¿åãªç®äžèèªã®è¥æºæ£è ã®éèãèŠèŠåããããšã¯ç¹å®ã®éèã®ç §æåšã®ããã«å°é£ã§ãã è£ çœ®ã¯10mmã®æ·±ããè¶ããŠçªãéãããšãã§ããŸããã æ£è æ§ã®æ¡çšãå¶éããŸãã ãŸããããåæã®çµç¹ã§èŠèªæ§ãé«ããããã«ã¯ãæè¡ã®é²æ©ãå¿ èŠã§ãã å ç¢ãªç ç©¶éçº(ç ç©¶éçº)æè³ã¯ããã®å¶éã«å¯ŸåŠããããšãã§ããŸãã
ã¢ããªã¹ããã¥ãŒ:
äžççãªéèã®ç §æè£ 眮åžå Žã¯æ¬¡ã®5幎äžã®åŒ·ãæé·ã®æœåšæ§ãæäŸããŸãã éèã€ã«ãããŒã·ã§ã³è£ 眮ã«å¯ŸããéèŠã¯ãé »ç¹ãªè¡æ¶²ã®åŒããå¿ èŠãšããç³å°¿ç ã®ãããªè¥æºé¢é£ã®æ¡ä»¶ã®äžæã®åªå é äœã«ãã£ãŠé転ãããŠããŸãã ãã®ãããªåé¡ã«å¯Ÿããããè匱ãªéå£ãæé·ãããããšã¯ããã©ã€ããŒãšããŠãæ©èœããŸãã éèã®å¯èŠæ§ãé«ããéã®ã€ã³ãµãŒãã®æ°ãæžãããçã¿ã軜æžãããªã©ã®éèç §æè£ 眮ã«ãã£ãŠæäŸãããå©ç¹ã¯ããã«ã¹ã±ã¢ãããã€ããŒéã®æ¡çšãçæåããŠããŸãã
åã¢ã¡ãªã«ã¯æ¥éã«å¢å ããç³å°¿ç ã®äººå£ãé«åºŠã®ãã«ã¹ã±ã¢ã®ã€ã³ãã©ã®å¯çšæ§ããã³è£ 眮æãæ»ãã«ããåžå Žãæ¯é ããŸãã ããããã¢ãžã¢ãã·ãã£ãã¯ã¯ãæãæ¥éã«æé·ããŠããå°ååžå Žã«ãªãããšãæåŸ ããŠããŸãã ããã¯ããã«ã¹ã±ã¢ãžã®ã¢ã¯ã»ã¹ãæ¹åããå»çããŒãªãºã ãäžæãããæ°èã¢ãžã¢ã®çµæžã«ãããæ©äŒãã¿ããããããã®äž»èŠãªåžå Žãã¬ãŒã€ãŒã®çŠç¹ãæé·ãããããšã«ãããã®ã§ãã
åžå ŽèŠæš¡ïŒç±³ãã«ïŒ Mn
CAGR10.8%
| èª¿æ»æé | 2025-2032 |
| æšå®ã®åºæºå¹Ž | 2024 |
| CAGR | 10.8% |
| æãæ¥æé·ããŠããåžå Ž | Asia Pacific |
| å€§èŠæš¡ãªåžå Ž | North America |
| åžå ŽéäžåºŠ | High |
| äž»èŠãã¬ãŒã€ãŒ | ã¢ãã¥ãã€ã³, ã¯ãªã¹ãã£ãŒã¡ãã£ã«ã«ããŒã«ãã£ã³ã°ã¹, ã·ã£ãŒã³ã»ã¢ãã»ã·ã¢, ãŽã§ãã¹ã³ãŒã, ZDå»ç ãã®ä» |
ãç¥ãããã ããïŒ
äžçã®éèç §æè£ 眮åžå Ž ãã¬ã³ã
- éèå ã«ããŒãã«ãšã®çµ±å: åžå ŽããªãŒããããã¬ãŒã€ãŒã¯ãéèå ã«ããŒãã«ã·ã¹ãã ãšéèå ç §ææè¡ãçµ±åããè¡ç®¡ã¢ã¯ã»ã¹ãæ¹åããŠããŸãã ããã¯ãæ¡åŒµãããèŠèŠåã®ããã®ã«ããŒãã«åãµã€ãã«çŽæ¥ç §æãæäŸããŸãã äŸãã°ã10æ 11, 2023, B. Braun Medical Inc.ã®å»çæ©åšã¡ãŒã«ãŒã¯ããã«ãã¢ã¯ã»ã¹è¡æ¶²å¶åŸ¡ãåããIntrocan Safety 2 IV Catheterãèµ·åããŸããã ããã¯IVããã»ã¹å šäœã§è¡ã®åºè¡ã®å±éºãæžããèªåéã®æ£ã®ä¿è·ããããŸãã
- ã¹ããŒããã©ã³ããŒã¹ã®éèã€ã¡ãŒãžã³ã°ã®æ¡çš: ã¹ããŒããã©ã³ããŒã¹ã®éèããžã¥ã¢ã©ã€ãŒãŒã·ã§ã³ã¯ãåžå Žã§æ°ãããã¬ã³ãã§ãã ã¹ããŒããã©ã³ã«Veinseek Proã¢ã¿ããã®ãããªããã€ã¹ã¯ãéèã€ã¡ãŒãžã³ã°çšã®ã«ã¡ã©ã§äœ¿çšãããŸãã ããã¯ããã倧ããªç§»æ€æ§ãšæé ãªäŸ¡æ ŒãæäŸããŸãã äŒæ¥ã¯ãéèã€ã¡ãŒãžã³ã°ã®ããã®ãŠãŒã¶ãŒãã¬ã³ããªãŒã§é«æ§èœãªã¢ãã€ã«ã¢ããªã®éçºã«æ³šåããŠããŸãã ã¹ããŒããã©ã³ã®çµ±ååŸåã¯ãçæã®æ¡çšã«æåŸ ãããŸãã
äžççãªéèç §æè£ 眮åžå Žã®å°åæŽå¯
ãã®ã¬ããŒãã®è©³çްã«ã€ããŠã¯ã ç¡æãµã³ãã«ã³ããŒãããŠã³ããŒã- åã¢ã¡ãªã« 2025幎ã®éèç §æè£ 眮åžå Žã®æå€§ã®ã·ã§ã¢ãä¿æããäžçåžå Žã®35.6%ãå ããèŠèŸŒã¿ã§ãã ããã¯ã倿°ã®å»çæ©é¢ãæ ¢æ§çŸæ£ã®é«ãåªå æ§ãå°åã«ãããéèç §æããã€ã¹ã®æé·æèã®ååšã«ãããã®ã§ãã ããšãã°ã2021幎2æã«ã¯ãæ³šå ¥çè·åž«ç€ŸäŒ(INS)ã«é¢ããå»çæ©åšã¡ãŒã«ãŒã®ã¢ããŠã³ã¹ã§ããAccuVein Inc.ã¯ãNIRNearèµ€å€ç·ãçšããéèå èŠé¡æ€æ»è£ çœ®ãæ¡çšããåšèŸºæ©åšã®è©äŸ¡ã«ããéèéžå®ãæ¯æŽããŠããŸãã
- ãšãŒããã 2025幎ã«äžçåžå Žã®29.3%ãå ããéèç §æè£ 眮ã®ããã®ç¬¬2äœåžå Žã§ããããšãæåŸ ãããŸãã ããã¯ãå°åã«ãããç³å°¿ç ãå¿è¡ç®¡çŸæ£ãªã©ã®æ ¢æ§çŸæ£ã®å¢å ã«ãããã®ã§ãã
- ã¢ãžã¢ãã·ãã£ã㯠äºå ±æéäžã«éèç §ææ©åšã®æéæé·åžå Žã§ããããšãæåŸ ãããŸãã ããã¯ãæé·ããå»çã€ã³ãã©ã®ããã§ãããŸã, éèç §æè£ çœ®ã®æèãé«ããŸã, ãããŠãå°åã§æ ¢æ§çŸæ£ã®å¢å€§.
ã»ã°ã¡ã³ãåæ äžçã®éèç §æè£ 眮åžå Ž
ãã®ã¬ããŒãã®è©³çްã«ã€ããŠã¯ã ç¡æãµã³ãã«ã³ããŒãããŠã³ããŒãç«¶åã®æŠèŠ äžçã®éèç §æè£ 眮åžå Ž
AccuveinãChristie Medical HoldingsãSharn麻é ãéèé¡ãZDã¡ãã£ã«ã«ãVivolightãCambridge MedicalïŒAsiaïŒPrivateãEvena MedicalãNear Infrared ImagingãVeinliteãïŒnbsp; ã·ã£ã«ã³éº»é ãïŒnbsp; Vino Optics Incã
äžçã®éèç §æè£ 眮åžå Ž ãªãŒããŒ
- ã¢ãã¥ãã€ã³
- ã¯ãªã¹ãã£ãŒã¡ãã£ã«ã«ããŒã«ãã£ã³ã°ã¹
- ã·ã£ãŒã³ã»ã¢ãã»ã·ã¢
- ãŽã§ãã¹ã³ãŒã
- ZDå»ç
æè¿ã®åå äžçã®éèç §æè£ 眮åžå Ž
- 4æ2022æ¥ å ç«ããã¯ãã€ãªã»ã³ã¿ãŒ ãã©ãºããããŒã·ã§ã³ã®ããã®ãã€ãªãã¯ãããžãŒäŒç€Ÿããã€ã³ãã¥ãŒã¢æè¡ãéå§ããŸããã 人ã«ããè¯ããããŒäœéšãæäŸããŸããã
- 2020幎7æãZDã®å»åŠ å»çæ©åšäŒç€Ÿãè¡ç®¡äœçœ®æ±ºããã€ã³ãã¡ã€ã³ããŒã·ã¹ãã ã匷åãããã€ã³èŠèŠåãªãã·ã§ã³ãæ¹åããŸããã
- 2021幎2æã ã¢ãã¥ãã€ã³æ ªåŒäŒç€Ÿ å»ççšæ©åšã¡ãŒã«ãŒã¯ãæ³šå ¥åºæºã¯ãè¿èµ€å€ç·(NIR)ã®è¡ç®¡å èŠé¡æ€æ»æè¡ããå§ãããŸãã åšèŸºå°åã®ãµã€ããè©äŸ¡ããéèéžæã«é¢ããããè©³çŽ°ãªæ å ±ã«åºã¥ããæ±ºå®ãä¿é²ããããã«äœ¿çšãããŸãã
äžçã®éèç §æè£ 眮åžå Ž ã»ã°ã¡ã³ããŒã·ã§ã³
- ãã¯ãããžãŒ
- èµ€å€ç·æŸå°
- ã«ã¹ã¿ãã€ãº
- è¶ é³æ³¢
- ãã®ä»
- çšéå¥
- éèã¢ã¯ã»ã¹
- è¡ã®åŒã
- å€ç§æè¡
- ãã®ä»
- ãšã³ããŠãŒã¶
- ç é¢
- ç®è¡ãã£ã³ã
- åŠè¡æ©é¢(ç ç©¶ã»åŠè¡æ©é¢ç)
- ãã®ä»
- å°åå¥
- åã¢ã¡ãªã«
- ãšãŒããã
- ã¢ãžã¢ãã·ãã£ãã¯
- ã©ãã³ã¢ã¡ãªã«
- äžæ±
- ã¢ããªã«
è³Œå ¥ãªãã·ã§ã³ãæ€èšããŸãã?ãã®ã¬ããŒãã®åã ã®ã»ã¯ã·ã§ã³?
Komal Dighe ã¯ãåžå Žèª¿æ»ãšã³ã³ãµã«ãã£ã³ã°ã§ 8 幎以äžã®çµéšãæã€çµå¶ã³ã³ãµã«ã¿ã³ãã§ãã圌女ã¯ããã«ã¹ãã㯠ã³ã³ãµã«ãã£ã³ã° ã¬ããŒãã§é«åè³ªã®æŽå¯ãšãœãªã¥ãŒã·ã§ã³ã管çããã³æäŸããããšã«åªããŠããŸãã圌女ã®å°éç¥èã¯ãäžæ¬¡èª¿æ»ãšäºæ¬¡èª¿æ»ã®äž¡æ¹ã®å®æœãã¯ã©ã€ã¢ã³ãã®èŠä»¶ãžã®å¹æçãªå¯Ÿå¿ãåžå Žã®æšå®ãšäºæž¬ã«åªããŠããŸãã圌女ã®å æ¬çãªã¢ãããŒãã«ãããã¯ã©ã€ã¢ã³ãã¯åŸ¹åºçãã€æ£ç¢ºãªåæãåãããããããæ å ±ã«åºã¥ããæææ±ºå®ãè¡ããåžå Žã®æ©äŒã掻çšã§ããŸãã
